CDMO RFP Response: How to Win More CRO and CDMO Business

For a CRO or CDMO, an RFP is the moment your entire business development effort gets tested. Months of relationship building, conference conversations, and inbound nurturing funnel down to one document and a deadline. Win it, and you book revenue that can span years. Lose it, and the capacity you reserved, the scientists you briefed, and the pricing you sweated over walk out the door with a competitor.

The uncomfortable truth is that most life sciences service companies treat RFPs reactively. A request lands in an inbox, someone panics, subject-matter experts get pulled off billable work, and a proposal goes out the door 48 hours before the deadline with no real strategy behind it. That approach leaves win rates on the table. This guide walks through how to build a repeatable, disciplined RFP process that lifts your close rate without burning out your technical team.

Key Takeaways

• Win rates hover around 45%, so half of your effort is wasted by default. The average RFP win rate reached about 45% in 2025, up from roughly 43% in 2024. Every proposal you send has, on average, worse than even odds unless you are qualifying and differentiating deliberately.

• Saying no is the highest-leverage move you can make. Companies that adopt a formal bid/no-bid process see win rates improve by roughly 15 to 25 percent within six months, often without changing how they write a single proposal.

• Speed and structure separate the top quartile. Top-performing teams reach win rates of 60 percent or higher, and the average proposal response time is about 25 hours, so a slow, ad hoc process is a competitive disadvantage.

• Price transparency wins trust. An RFP sticker price typically covers only about 60 to 70 percent of the true relationship cost, so sponsors reward CDMOs and CROs that are upfront about tech transfer, change orders, and scale-up economics.

• The market rewards good process. With roughly 72 percent of pharma companies outsourcing manufacturing and outsourcing penetration near 40 percent of pharmaceutical manufacturing, RFP volume is rising, and a scalable response engine is now a growth requirement, not a nice-to-have.

Why the RFP Is the Real Battleground for CROs and CDMOs

Outsourcing is no longer the exception in drug development; it is the operating model. About 72 percent of pharmaceutical companies now outsource manufacturing to CDMOs to focus on R&D and reduce capital expenditure, and outsourcing penetration has climbed to roughly 40 percent of total pharmaceutical manufacturing, up from about 30 percent in 2018, according to market analyses compiled by Fortune Business Insights. The overall CDMO market is estimated somewhere between roughly 211 and 275 billion US dollars for 2026, growing at a 6 to 10 percent CAGR, with biologics capacity expanding faster still at about 12 to 15 percent annually.

More outsourcing means more RFPs, and more RFPs means more noise. Proposal teams now field an average of about 166 submissions per year, a number that keeps climbing as economic pressure pushes buyers to competitively bid more work. The companies that thrive are not the ones that respond to everything. They are the ones that respond to the right things, exceptionally well.

If your pipeline is not consistently generating qualified RFP invitations in the first place, the response process matters less than the demand engine behind it. Our guide to pipeline optimization for life sciences covers how to build that predictable flow before we ever get to the proposal stage.

Step 1: Qualify Before You Commit (the Bid/No-Bid Decision)

The single biggest lever on your win rate is the decision you make before you write anything. This is the bid/no-bid gate, and most CROs and CDMOs skip it entirely.

The data here is striking. Top performers with win rates of 60 percent or higher submit about 81 percent of their bids only after a formal go/no-go decision. Organizations that apply a consistent scoring framework typically achieve win rates of 40 to 60 percent, compared with the 10 to 20 percent seen in teams that chase every opportunity, per analysis from Loopio and Bidara. As proposal strategist Bob Lohfeld frames it, the key to good bid decisions is not picking the deals you will win, but discarding the deals you will lose.

A practical bid/no-bid scorecard for a life sciences service company should weigh:

• Technical fit: Do you have genuine experience with this modality, platform, or indication, or would you be learning on the sponsor's dime?

• Capacity and timeline: Can you actually deliver the requested scale and milestones without displacing existing clients?

• Relationship warmth: Did this RFP arrive cold, or is it the result of prior conversations? Cold, wired-for-someone-else RFPs are where win rates go to die.

• Strategic value: Does the account fit your target profile, or is it a one-off that will strain your team?

• Commercial viability: Is the budget realistic for the scope, and does the deal clear your margin threshold?

Score every incoming RFP, and give your team permission to decline. Declining a poorly fit RFP is not lost revenue; it is reclaimed capacity you can pour into a proposal you can actually win.

Step 2: Decode What the Sponsor Is Really Asking

A strong CDMO RFP response starts with reading between the lines. A well-run RFP will include a project overview, a detailed scope of work (process development, analytical method validation, cGMP manufacturing), a technical package on the molecule and process, capacity and scale requirements, and a milestone timeline. But the document rarely states the sponsor's real anxieties, and those anxieties are what you must answer.

Emerging pharma sponsors, in particular, are betting the future of their program on your site. According to selection guidance from Outsourced Pharma and IntuitionLabs, buyers evaluate responses against technical expertise, regulatory track record, quality systems, operational capacity, financial stability, and cultural fit, usually through a weighted scoring matrix. The differentiators that move those scores are your specific experience with the required manufacturing platform, the depth and availability of your analytical capabilities, your history of successful regulatory interactions and facility inspections, and the responsiveness of your project management structure.

So when you respond, do not just confirm you can do the work. Show evidence: comparable programs, inspection history, tech transfer timelines you have actually hit, and named project managers with real availability. Specificity beats capability claims every time.

Step 3: Respond Fast, and Respond Consistently

Speed matters more than teams assume. The average proposal response time is about 25 hours, and the fastest teams win partly because they have removed friction from the process. That speed does not come from heroics; it comes from infrastructure. A maintained content library of pre-approved technical answers, capability statements, quality-system descriptions, and case studies lets you assemble 70 percent of a proposal in hours, so your experts spend their time on the 30 percent that is genuinely bespoke.

This is also where technology is reshaping the field. AI adoption among proposal teams doubled to about 68 percent, and CDMOs using AI-assisted RFP workflows report 40 to 60 percent faster turnaround with higher win rates, because they can pursue more qualified opportunities without diluting quality, according to Inventive.ai and Percepture. The goal is not to automate judgment; it is to automate assembly so your senior people can focus on strategy and differentiation.

Step 4: Price With Total Cost of Ownership in Mind

Pricing is where trust is won or lost. Sophisticated sponsors know that the number on your proposal is not the number they will pay. Analysis from DrugPatentWatch suggests the RFP sticker price often covers only about 60 to 70 percent of what the relationship will actually cost, with the balance hiding in technology transfer fees, raw material markups, stability storage accumulation, change order inflation, and internal management overhead.

You can use this to your advantage. When you present pricing transparently, flagging where change orders typically arise and how you manage scope, you signal partnership rather than a bait-and-switch. Sponsors who have been burned by hidden costs will remember the vendor who told them the truth upfront.

RFP Response: Reactive Scramble vs. Disciplined Engine

The gap between how most CROs and CDMOs handle RFPs and how the winners do it is stark. The table below contrasts the two approaches and the outcomes each tends to produce.

Dimension	Reactive scramble	Disciplined engine
Qualification	Respond to every RFP that arrives	Formal bid/no-bid scorecard on each request
Typical win rate	About 10 to 20 percent	About 40 to 60 percent, top quartile 60 percent plus
Response speed	Days, often last-minute	Hours, powered by a content library (about 25h average)
Content	Rewritten from scratch each time	Pre-approved library plus bespoke differentiation
Pricing	Sticker price only	Transparent total cost of ownership
Team impact	Experts pulled off billable work in crisis mode	Experts focused on the 30 percent that wins
Six-month effect	Flat or declining win rate	Win rate up roughly 15 to 25 percent

The point is not that the disciplined column requires more effort. Often it requires less, because you stop pouring energy into proposals you were never going to win.

Where Business Development Strategy Fits In

A great proposal cannot rescue a cold relationship. The RFPs you win are usually the ones where you were already a trusted name before the document arrived, which is why proposal performance is inseparable from your broader business development strategy. If you are fielding RFPs that consistently feel wired for a competitor, the fix is upstream: earlier engagement, better positioning, and warmer relationships.

This is a familiar theme in the challenges we see across the industry, whether you are a manufacturer navigating business development challenges for CDMOs or a research organization working through business development challenges for small and mid-sized CROs. For companies that lack the internal bandwidth to build this engine, a fractional business development model can supply both the demand generation and the proposal discipline needed to convert more RFPs into signed contracts.

Frequently Asked Questions

What is a good RFP win rate for a CRO or CDMO?

The cross-industry average is about 45 percent as of 2025, with healthcare specifically near 44 percent. Top-performing teams reach 60 percent or higher. If you are pursuing every RFP indiscriminately, your win rate is more likely in the 10 to 20 percent range, which signals a qualification problem rather than a proposal-writing problem.

How quickly should we respond to an RFP?

The average proposal response time is around 25 hours, and faster teams tend to win more. The way to hit that speed sustainably is a maintained content library of pre-approved answers, so your technical experts only spend time on the genuinely custom portions of each response.

Should we respond to every RFP we receive?

No. This is the most important discipline in the entire process. Companies that adopt a formal bid/no-bid gate improve win rates by roughly 15 to 25 percent within six months. Declining poorly fit RFPs frees capacity for the proposals you can actually win.

What do pharma sponsors weigh most when scoring a CDMO RFP response?

Most sponsors use a weighted scoring matrix covering technical expertise, regulatory and inspection track record, quality systems, operational capacity, financial stability, and cultural fit. The strongest differentiators are specific platform experience, analytical depth, proven regulatory interactions, and responsive project management, all backed by evidence rather than claims.

How should we handle pricing in a proposal?

Price with total cost of ownership in mind. Because a sticker price often reflects only 60 to 70 percent of the real relationship cost, transparency about tech transfer, change orders, and scale-up economics builds trust and differentiates you from vendors that lowball to win and true up later.

Sources

• Bidara, RFP Statistics 2026: https://www.bidara.ai/research/rfp-statistics

• Loopio, Statistics on RFP Win Rates & Proposal Management: https://loopio.com/blog/rfp-statistics-win-rates/

• Inventive.ai, RFP Response Trends and Benchmarks 2026: https://www.inventive.ai/blog-posts/rfp-response-trends-benchmarks

• Percepture, CDMO Marketing Strategy and Qualified RFPs: https://percepture.com/life-sciences-insights/cdmo-marketing/

• Outsourced Pharma, Identifying and Selecting a CDMO: https://www.outsourcedpharma.com/topic/identifying-selecting-cdmo

• IntuitionLabs, CDMO Selection Guide: Due Diligence, Scorecards & KPIs: https://intuitionlabs.ai/articles/cdmo-selection-guide

• DrugPatentWatch, CDMO Pricing: Total Cost of Ownership Playbook: https://www.drugpatentwatch.com/blog/the-ultimate-guide-to-cdmo-pricing/

• Fortune Business Insights, CDMO Outsourcing Market: https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502